Articles

In a roundtable discussion hosted by HHS, health insurers pledged 6 key reforms they say are designed to cut red tape, accelerate care decisions, and enhance

The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center.

Paula Aristizabal, MD, MAS, a pediatric hematologist/oncologist at Rady Children’s Hospital-San Diego/associate professor at the University of California San Diego, and her research team developed a peer navigation intervention known as the Childhood Malignancy Peer Research Navigation (Comprendo) program. This program pairs trained parent navigators—individuals who have experienced similar challenges with their own children’s cancer care—with parents who are newer to the experience, with the intention to guide these families through the informed consent process for childhood cancer clinical trials.

Value-Based Cancer Care is pleased to share with you that we are on site at the 21st Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, April 9-12, 2025, in Portland, OR and together with our sister publication, the Journal of Hematology Oncology Pharmacy,we are bringing you live coverage and abstracts from the meeting.

n the US cohort, Black patients with HR-positive/HER2-negative mBC who underwent NGS testing were more likely to receive first-line chemotherapy, less likely to have PIK3CA mutations, and less likely to receive first-line CDK4/6 inhibitors compared with White patients.

round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.